CALIFA, the Calar Alto Legacy Integral Field Area survey: IV. Third public data release

This paper describes the third public data release (DR3) of the Calar Alto Legacy Integral Field Area (CALIFA) survey. Science-grade quality data for 667 galaxies are made public, including the 200 galaxies of the second public data release (DR2). Data were obtained with the integral-field spectrograph PMAS/PPak mounted on the 3.5 m telescope at the Calar Alto Observatory. Three different spectral setups are available: i) a low-resolution V500 setup covering the wavelength range 3745-7500 Å (4240-7140 Å unvignetted) with a spectral resolution of 6.0 Å (FWHM) for 646 galaxies, ii) a medium-resolution V1200 setup covering the wavelength range 3650-4840 Å (3650-4620 Å unvignetted) with a spectral resolution of 2.3 Å (FWHM) for 484 galaxies, and iii) the combination of the cubes from both setups (called COMBO) with a spectral resolution of 6.0 Å and a wavelength range between 3700-7500 Å (3700-7140 Å unvignetted) for 446 galaxies. The Main Sample, selected and observed according to the CALIFA survey strategy covers a redshift range between 0.005 and 0.03, spans the color-magnitude diagram and probes a wide range of stellar masses, ionization conditions, and morphological types. The Extension Sample covers several types of galaxies that are rare in the overall galaxy population and are therefore not numerous or absent in the CALIFA Main Sample. All the cubes in the data release were processed using the latest pipeline, which includes improved versions of the calibration frames and an even further improved image reconstruction quality. In total, the third data release contains 1576 datacubes, including ~1.5 million independent spectra.Fil: Sánchez, S. F.. Universidad Nacional Autónoma de México; MéxicoFil: Garciá Benito, R.. Instituto de Astrofísica de Andalucía; EspañaFil: Zibetti, S.. Osservatorio Astrofisico di Arcetri; ItaliaFil: Walcher, C. J.. Leibniz-Institut für Astrophysik Potsdam; AlemaniaFil: Husemann, B.. European Southern Observatory; AlemaniaFil: Mast, Damian. Universidad Nacional de Cordoba. Observatorio Astronomico de Cordoba; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba; ArgentinaFil: López Fernández, R.. Instituto de Astrofísica de Andalucía; EspañaFil: López Sánchez, A. R.. Sydney Institute for Astronomy; AustraliaFil: Lyubenova, M.. University of Groningen. Kapteyn Astronomical Institute; Países BajosFil: Marino, R.. Institut für Astronomie; SuizaFil: Márquez, I.. Instituto de Astrofísica de Andalucía; EspañaFil: Mendez Abreu, J.. University of St. Andrews. School of Physics and Astronomy; Reino UnidoFil: Mollá, M.. Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas; EspañaFil: Monreal Ibero, A.. Université Paris Diderot. Observatoire de Paris; FranciaFil: Ortega Minakata, R.. Universidade Federal do Rio de Janeiro. Observatorio do Valongo; BrasilFil: Torres Papaqui, J. P.. Universidad de Guanajuato. Departamento de Astronomía; MéxicoFil: Pérez, E.. Instituto de Astrofísica de Andalucía; EspañaFil: Rosales Ortega, F. F.. Instituto Nacional de Astrofísica, Óptica y Electrónica; MéxicoFil: Roth, M. M.. Leibniz-Institut für Astrophysik Potsdam; AlemaniaFil: Sánchez Blázquez, P.. Universidad Autónoma de Madrid. Facultad de Ciencias. Departamento de Física Teórica; EspañaFil: Schilling, U.. Ruhr-Universität Bochum. Astronomisches Institut; AlemaniaFil: Spekkens, K.. Royal Military College of Canada. Department of Physics; CanadáFil: Vale Asari, N.. Universidade Federal de Santa Catarina. Departamento de Física; BrasilFil: Van Den Bosch, R. C. E.. Max-Planck-Institut für Astronomie; AlemaniaFil: Van De Ven, G.. Max-Planck-Institut für Astronomie; AlemaniaFil: Vilchez, J. M.. Instituto de Astrofísica de Andalucía; EspañaFil: Wild, V.. University of St. Andrews. School of Physics and Astronomy; Reino UnidoFil: Wisotzki, L.. Leibniz-Institut für Astrophysik Potsdam; AlemaniaFil: Ylldlrlm, A.. Max-Planck-Institut für Astronomie; AlemaniaFil: Ziegler, B.. Department of Astrophysics. University of Vienna; Austri

Flares in IIMs and the timeline following COVID-19 vaccination: a combined analysis of the COVAD-1 and -2 surveys

Objectives: Disease flares in the post-coronavirus disease 2019 (COVID-19) vaccination period represent a prominent concern, though risk factors are poorly understood. We studied these flares among patients with idiopathic inflammatory myopathies (IIMs) and other autoimmune rheumatic diseases (AIRDs). Methods: The COVAD-1 and -2 global surveys were circulated in early 2021 and 2022, respectively, and we captured demographics, comorbidities, AIRDs details, COVID-19 infection history and vaccination details. Flares of IIMs were defined as (a) patient self-reported, (b) immunosuppression (IS) denoted, (c) clinical sign directed and (d) with >7.9-point minimal clinically significant improvement difference worsening of Patient-Reported Outcomes Measurement Information System (PROMIS) PROMISPF10a score. Risk factors of flares were analysed using regression models. Results: Of 15 165 total respondents, 1278 IIMs (age 63 years, 70.3% female, 80.8% Caucasians) and 3453 AIRDs were included. Flares of IIM were seen in 9.6%, 12.7%, 8.7% and 19.6% patients by definitions (a) to (d), respectively, with a median time to flare of 71.5 (10.7-235) days, similar to AIRDs. Patients with active IIMs pre-vaccination (OR 1.2; 95% CI 1.03, 1.6, P = 0.025) were prone to flares, while those receiving rituximab (OR 0.3; 95% CI 0.1, 0.7, P = 0.010) and AZA (OR 0.3, 95% CI 0.1, 0.8, P = 0.016) were at lower risk. Female gender and comorbidities predisposed to flares requiring changes in IS. Asthma (OR 1.62; 95% CI 1.05, 2.50, P = 0.028) and higher pain visual analogue score (OR 1.19; 95% CI 1.11, 1.27, P < 0.001) were associated with disparity between self-reported and IS-denoted flares. Conclusion: A diagnosis of IIMs confers an equal risk of flares in the post-COVID-19 vaccination period to AIRDs, with active disease, female gender and comorbidities conferring a higher risk. Disparity between patient- and physician-reported outcomes represents a future avenue for exploration

Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: A comparative analysis of the COVAD surveys

Objective: COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs); however, hesitancy continues to persist among these patients. Therefore, we studied the prevalence, predictors and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. Methods: The first and second COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analysed using regression models in different groups. Results: We analysed data from 18 882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) (OR: 0.26; 95% CI: 0.24, 0.30, P < 0.001). However, concerns/fear over long-term safety had increased (OR: 3.6; 95% CI: 2.9, 4.6, P < 0.01). We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs (OR: 1.8; 95% CI: 1.08, 3.2, P = 0.023) and HCs (OR: 4; 95% CI: 1.9, 8.1, P < 0.001), as well as more long-term safety concerns/fear (IIMs vs AIRDs - OR: 1.9; 95% CI: 1.2, 2.9, P = 0.001; IIMs vs HCs - OR: 5.4 95% CI: 3, 9.6, P < 0.001). Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. Conclusion: Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function